医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Toshiba Announces Business Vision for Southeast Asia

2014年09月24日 PM03:00
このエントリーをはてなブックマークに追加


 

JAKARTA, Indonesia

Mr. Hisao Tanaka, the President and CEO of Japan’s Toshiba Corporation (TOKYO:6502), today announced Toshiba’s comprehensive strategy for expanding its business in Southeast Asia, including investing US$1 billion dollars in the region over the next five years, and doubling its current sales to $7 billion dollars.

Speaking at a press conference in Jakarta, Indonesia, Mr. Tanaka detailed the infrastructure technologies and know-how that Toshiba proposes to deploy in Southeast Asia in support of building a better future and securing a safe, secure and comfort society.

Underlining the importance of Southeast Asia to Toshiba, Mr. Tanaka explained that for Toshiba, Southeast Asia has long been a strategic manufacturing hub for Toshiba’s major businesses, including semiconductors, hard disk drives and SSD in the Storage business, transmission and distribution equipment and industrial motors, and TVs and home appliances.

Building on this, the company will shortly start operation of a new infrastructure business in Indonesia, part of a regional network it is putting in place, and is also promoting major initiatives in healthcare, as Mr. Tanaka noted: “We are building a new medical equipment manufacturing plant in Malaysia, alongside the medical equipment sales company we established this June. We recently positioned healthcare as one of our three main pillars of business.”

Looking at relations between Southeast Asia and Japan, Mr. Tanaka referenced a recent survey which found that 33% of people in the region, by far the largest group, considered Japan to be the most reliable partner. He commented: “Southeast Asia currently enjoys positive benefits Japan does not have, including high economic growth and a young, highly capable workforce, and that hands of friendship adds to the importance of our partnership.” He added, “We have located many important strategic manufacturing hubs in the region. And because of this, ensuring stable power supply, putting in place disaster prevention measures and upgrading social infrastructure, are all as important to us as they are to people here.”

Toshiba’s plan to invest billion dollars in Southeast Asia, the same amount the group has invested in the region over the last 20 years. Mr. Tanaka explained, “Southeast Asia is dynamic and forward looking, and so is Toshiba. More than anything else, I want Toshiba Group to engage deeply in Southeast Asia, to understand and respond to the unique qualities of each country. Guided by our long-standing values and local wisdom, I want Toshiba to grow in harmony with the countries and communities of Southeast Asia, and to achieve our vision of creating a safe, secure and comfortable society, the ‘Human Smart Community”

About Toshiba
Toshiba Corporation, a Fortune Global 500 company, channels world-class capabilities in advanced electronic and electrical product and systems into five strategic business domains: Energy & Infrastructure, Community Solutions, Healthcare Systems & Services, Electronic Devices & Components, and Lifestyles Products & Services. Guided by the principles of The Basic Commitment of the Toshiba Group, “Committed to People, Committed to the Future”, Toshiba promotes global operations towards securing “Growth Through Creativity and Innovation”, and is contributing to the achievement of a world in which people everywhere live safe, secure and fulfilled lives.

Founded in Tokyo in 1875, today’s Toshiba is at the heart of a global network of over 590 consolidated companies employing over 200,000 people worldwide, with annual sales surpassing 6.5 trillion yen (US$63 billion).
To find out more about Toshiba, visit www.toshiba.co.jp/index.htm

CONTACT

Toshiba Press Contact:
Hirokazu Tsukimoto, 81-3-3457-2100
Public
Relations & Investor Relations Office
Corporate Communications
Div.
hirokazu.tsukimoto@toshiba.co.jp

同じカテゴリーの記事 

  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表
  • The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report